No black box warning on record for Nipent

As of the latest FDA labeling reviewed, Nipent (PENTOSTATIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nipent medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS See Boxed Warning . Patients with hairy cell leukemia may experience myelosuppression primarily during the first few courses of treatment. Patients with infections prior to NIPENT treatment have in some cases developed worsening of their condition leading to death, whereas others have achieved complete response. Patients with infection should be treated only when the potential benefit of

No black box warning on record for Nipent

Other warnings & precautions

WARNINGS See Boxed Warning . Patients with hairy cell leukemia may experience myelosuppression primarily during the first few courses of treatment. Patients with infections prior to NIPENT treatment have in some cases developed worsening of their condition leading to death, whereas others have achieved complete response. Patients with infection should be treated only when the potential benefit of

Nipent Black Box Warning

No black box warning on record for Nipent

Other warnings & precautions

Nipent Black Box Warning

No black box warning on record for Nipent

Other warnings & precautions